April 6, 2022 8:04am

There is risk weakness bubbling beneath the surface

Pre-open indications: holding my cards although 1 Pimp/Pump and Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are Down -0.65% (-225 points), S&P futures are DOWN -0.92% (-42 points) and NASDAQ futures are DOWN -1.53% (-237 points)

 

Stock futures dived on Wednesday in early premarket trade as investors await the release of the Fed’s meeting minutes and to reduce the central bank’s balance sheet.

European markets declined,

Asia-Pacific markets also declined with Chinese tech stocks in Hong Kong falling sharply.

 

Henry’omics:

Minutes from the Fed’s most-recent meeting are slated for release Wednesday afternoon.

Rates soared to new heights as investors bet the Fed is about to aggressively tighten policy to fight inflation, and in turn slow the economy.

The 10-year Treasury yield jumped above 2.65% on Wednesday, hitting a three-year high and continuing its rapid climb this week. The rate ended Monday at 2.40%.

Today session could sort-out the changes and risks to going forward.

 

RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: rough ride with news spelling share pricing risk.” … https://www.regmedinvestors.com/articles/12375

 

Ebb and flow –

Q2/22 – 2 positive and 1 negative close

Q1/22:

·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  (35 to date -some dropped a couple added)

 

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed up again +$0.59 with 8,743 shares trading after Monday +$0.49 with 8,809 shares traded, Friday’s flat with 16 shares traded, Thursday’s -$0.10 with 124 shares traded, Wednesday’s +$0.50 with 3,932 shares traded, and last Tuesday’s -$0.50 with 3,330 shares traded. Post a VERY questionable earning’s release WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion?

 

The BOTTOM LINE: reiterating, "I think and feel even if not today, the cell and gene therapy sector is in the midst of a yet … another slow pullback."

It is all dependent on the stock market …

Is this a signal for a return of sector rotation?

Reiterating, keep positions small and diversified amid modest overall exposure to limit any fallout. Taking profits quickly and cutting losers quickly is still vital

Reiterating, “An odd quote that caught my eye and some feelings, “To paraphrase the Rolling Stones, you can't always get what you want, but sometimes you get what you need.”

Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.